Titlebook: Innovative Antimetabolites in Solid Tumours; Matti S. Aapro Conference proceedings 1994 Springer-Verlag Berlin Heidelberg 1994 Antimetabol

ACID

書目名稱Innovative Antimetabolites in Solid Tumours影響因子(影響力)




書目名稱Innovative Antimetabolites in Solid Tumours影響因子(影響力)學(xué)科排名




書目名稱Innovative Antimetabolites in Solid Tumours網(wǎng)絡(luò)公開度




書目名稱Innovative Antimetabolites in Solid Tumours網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Innovative Antimetabolites in Solid Tumours被引頻次




書目名稱Innovative Antimetabolites in Solid Tumours被引頻次學(xué)科排名




書目名稱Innovative Antimetabolites in Solid Tumours年度引用




書目名稱Innovative Antimetabolites in Solid Tumours年度引用學(xué)科排名




書目名稱Innovative Antimetabolites in Solid Tumours讀者反饋




書目名稱Innovative Antimetabolites in Solid Tumours讀者反饋學(xué)科排名

GOAD

reptile

Thymidylate Synthase Inhibitors, Modulation of 5-Fluorouracil and Folate Analogues,to clinical practice. The effects of 5-fluorouracil on the cell are 1) inhibition of thymidylate synthase, 2) a direct effect on DNA, and 3) a direct effect on RNA [1]. These mechanisms and their modulation by other factors designed to increase activation, response rates and survival, will be discus

Gratulate

A Review of Fludarabine and Cladribine in Solid Tumours,ancies such as hairy cell leukaemia, low-grade non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia, Waldenstr?m macroglobulinaemia and cutaneous T-cell lymphoma [1,2]. Both have also been used in acute leukaemias and fludarabine appears particularly promising for this indication [3]. Activation of

山崩

Gemcitabine in Ovarian Cancer,dard practice. It is obvious that new drugs are needed to improve the results in advanced disease. Recently the introduction of taxanes in the treatment of ovarian cancer has engendered hope that treatment may further improve. Gemcitabine is another promising candidate to be added to the list of dru

發(fā)牢騷

Gemcitabine Therapy in Non-Small Cell Lung Cancer: A Review,last decade. Few single agents have, in large studies, achieved response rates of more than 15%, while combination treatment gives response rates of 25% to 35% [1–4]. Several randomised studies comparing chemotherapy with best supportive care have yielded predominantly slightly favourable results fo

DUCE

Deduct

BILK

鑲嵌細工

A Review of Fludarabine and Cladribine in Solid Tumours,nce between activation and degradation appears crucial for their clinical activity [4]. FAMP and CDA are cytotoxic not by inducing necrosis but rather programmed cell death, apoptosis, by means of activation of specific endonucleases [5].